Homocysteine does not occur in the diet but it is an essential intermediate
in normal mammalian metabolism of methionine, Each compound, methionine or
homocysteine, is the precursor of the other. Similarly, the synthesis of o
ne is the mechanism for the detoxification of the other. The ubiquitous met
hionine cycle is the metabolic basis for this relationship. In some tissues
the transsulfuration pathway diverts homocysteine from the cycle and provi
des a means for the synthesis of cysteine and its derivatives. Methionine,
(or homocysteine) metabolism is regulated by the disposition of homocystein
e between these competing sequences. Both pathways require vitamin-derived
cofactors, pyridoxine for transsulfuration and both folate and cobalamin in
the methionine cycle. The clinical consequences of disruption of these pat
hways was apparent first in rare inborn errors of metabolism that cause hom
ocystinuria, but recent studies focus on "hyperhomocysteinemia" - a lesser
metabolic impairment that may result from genetic variations, acquired path
ology. toxicity and nutritional inadequacy. Hyperhomocysteinemia is an inde
pendent risk; factor for thrombovascular diseases however it is not clear w
hether the minimally increased concentration of the amino acid is the causa
tive agent or merely 3 marker for the pathology. Until we resolve that ques
tion we cannot predict the potential efficacy of therapies based on folate
administration with or without additional cobalamin and pyridoxine. Publish
ed by Elsevier Science Ltd.